advancing muscular dystrophy research

Website below is currently under constructionmdcrc logo

University of Washington
Department of Neurology


The Chamberlain laboratory is focused on understanding and developing treatments for the muscular dystrophies and other disorders of muscle. These studies center on the Duchenne muscular dystrophy (DMD) gene (dystrophin) and exploring the expression and function of these genes and the LGMD2I gene (FKRP).

A major area of focus involves the development of vectors to deliver dystrophin or other genes to muscle for gene therapy. These vectors are being tested for safety and for their ability to halt and/or reverse the dystrophic phenotype. The primary vector being studied is derived from adeno-associated virus (AAV), which efficiently transfers genes to skeletal muscle and heart. Methods are being developed for whole body systemic delivery, and a human clinical trial is being planned.

An additional area of study is an investigation of muscle stems cells and their potential use in ex vivo gene therapy following transduction of cells with lentiviral vectors, or by direct gene correction using AAV.

Our efforts to transfer genes to muscle are also being adapted for genetic and non-genetic muscle wasting disorders.

Jeff Chamberlain's can be found on here on addgene Plasmids shared on Addgene

Home | Research | News | Events | Lab Members | Publications | Benefactors | Contact Us